The angst generated by Macquarie is overdone. I have...

The angst generated by Macquarie is overdone. I have reservations about the analyst but at the end of the day, they're just another bloody broker. If the desk jockey or the firm gets an order, I can assure you they couldn't give a toss if it's a "buy" or "sell" order, all that counts is the commission. The recent stats, if they are to be believed, may merely represent short-covering, or, alternatively, if an institution wanted to secure stock without unduly disturbing the market, what better place to go than Macquarie, given their known "sell" stance on the stock? The above is all conjecture, but, it's all pretty irrelevant.
What's more interesting to me is the analysis of the data released by MSB last week from their Phase 2 CHF trial, and the news yesterday from Cell Therapies, (an unlisted UK based company,) following clinical trial results using allogeneic cells in open heart surgery for Class 4 candidates.
As reported, the MSB/Teva trial showed that there were no adverse effects in heart failure patients treated with Revascor after a 3 year period (30% MACE in Class 2 and 70% in later CHF controls)
Cell Therapies modified stem cells were injected into 11 Class 4 heart failure candidates undergoing heart surgery and after 2 years, all patients survived cf. average mortality rates of 70% for patients using existing treatments.
More than anyone, I appreciate that the no's are tiny, (30 in MSB trial, 11 in Cell Therapies trial) but the absence of MACE is impressive. And these tests would indicate that the sicker the patient, the more effective the treatment. It all goes to further validate MSB/Teva's success in gaining FDA approval to shift the focus of the Revascor Phase 3 trials to late stage CHF patients to seek a faster path to commercialisation.
And Silviu addressed the Royal Society in London today...he has more success gaining the attention of his peers, including Nobel Prize-winning scientests, than he does in gaining a hearing from the towering intellectuals running money in Australia.